Abstract:We report the expression of tissue factor pathway inhibitor-2 (TFPI-2) (also known as PP-5, placental protein-5; MSPI, matrix-associated serine protease inhibitor) in E. coli as a 25-kDa nonglycosylated protein with a glycine substituted for aspartic acid at the amino terminus. High-level expression of TFPI-2 was obtained with pRE1 expression vector under the transcriptional and translational controls of the lambdaP(L) promoter and lambdacII ribosome-binding site, respectively, with ATG initiation codon. TFPI-2 was produced as inclusion bodies and accounted for 25-30% of the total E. coli proteins. The inclusion bodies containing TFPI-2 were solubilized with urea, sulfitolyzed, purified, and refolded through a disulfide interchange reaction. The refolded E. coli TFPI-2 inhibited plasmin with an inhibition constant (K(i)) of 5 nM that is similar with the TFPI-2 expressed in a mammalian system. The refolded E. coli TFPI-2 bound heparin and also inhibited plasmin, regardless of whether the enzyme was in the fluid phase or was bound to the membranes of HT-1080 fibrosarcoma cells. In addition, refolded E. coli TFPI-2 inhibited radiolabeled matrix degradation and Matrigel matrix invasion by HT-1080 fibrosarcoma cells and B16-F10 melanoma cells. Together, our results suggest that glycosylation is not essential for antiprotease, antitumor, and matrix-binding activities of TFPI-2. Based on these collective data, we conclude that a biologically active nonglycosylated TFPI-2 can be produced in E. coli and that the protein can be produced in high-enough quantities to conduct in vivo studies for determination of the role of this inhibitor in tumor invasion and metastasis.

Expression and Anticoagulant Activity Analysis of Trx-NAPc2 Fusion Protein

Construction of Recombinant NNMT Plasmid and Expression in E. Coli

High Level Expression, Purification and Characterization of Active Fusion Human C1q and Tumor Necrosis Factor Related Protein 2 (hctrp2) in Escherichia Coli

[Cloning Expression and Characterization of a Multifunctional Anticoagulated Peptide Gene in E. Coli].

Expression of Hirulog 18in E.coli and the Test of its Biological Activity

Expression and Characterization of Thrombin Inhibitor TTI

Expression and characterization of fusion pro-tein hTNFα -hPgnK5 containing thrombin cleav-age site in E. coli

Expression and Bioactivity Analysis of the His-tagged Staphylococcal Enterotoxin C2

Gene Expression and Activity Analysis of a Novel Fusion Protein (Rgd)3/ttf

[High Level Expression of Human Atrial Natriuretic Peptide in Fusion Form in E. Coli System].

Generation of Bioactive Recombinant Ancylostoma Caninum Anticoagulant Peptide C2.

[Construction and expression of protein self-splicing prokaryotic expression vector pTWIN1- AcAPc2]

Expression and Activities Analysis of a Fusion Protein CREKA/tTF

Prokaryotic Expression and Biological Activity Identification of Tir of Enterohemorrhagic Escherichia Coli

Prokaryotic expression, purification, and reconstitution of biological activities (Antiprotease, antitumor, and heparin-binding) for tissue factor pathway inhibitor-2

[Construction of Novel Thioredoxin Fusion Protein Expression System and the Production of Recombinant Lf-CATH2].

Biological Function of Fusion Protein ATF-PAI2CD

Expression and Bioactive of TAT-NPY Fusion Protein

Prokaryotic Expression of SA-hirudin-RGD Fusion Proteinand Identification of Its Anticoagulant and Anti-platelet Aggregation Function

Molecular Cloning, Fusion Expression and Bioactivity of Pro-Nattokinase Gene

Expression of Activity Reteplase in E.coli